Detailed Description Type 2 Diabetes Mellitus (T2DM) and obesity are major global health
burdens with shared pathophysiological mechanisms, including insulin resistance, chronic
inflammation, and altered lipid metabolism. SGLT2 inhibitors, such as empagliflozin and
dapagliflozin, have emerged as effective glucose-lowering agents that also offer
additional benefits, including weight reduction, cardiovascular protection, and renal
function preservation.

Despite these advantages, the therapeutic response to SGLT2 inhibitors is variable, often
influenced by individual genetic differences. A key genetic determinant is CYP8B1
(cytochrome P450 family 8 subfamily B member 1), a gene encoding sterol
12-alpha-hydroxylase, which regulates bile acid synthesis and lipid metabolism.
Polymorphisms in CYP8B1 may impact drug metabolism and alter bile acid-mediated metabolic
regulation, potentially affecting both the efficacy and safety profile of SGLT2
inhibitors.

This clinical trial aims to investigate the role of CYP8B1 genetic variations in
modifying the clinical and biochemical responses to empagliflozin and dapagliflozin
therapy among obese patients recently diagnosed with T2DM.

Participants will be randomized into three groups:

- Group 1: Empagliflozin 10 mg daily

- Group 2: Dapagliflozin 10 mg daily

- Group 3 (Control): Standard care (lifestyle modification and/or metformin)

The intervention period is 6 months, during which multiple parameters will be monitored:

1. Obesity-Related Metrics: Body weight, BMI, waist circumference, and body fat
percentage.

2. Adipokines: adiponectin.

3. Lipid Profile: Total cholesterol, HDL, LDL, and triglycerides.

4. Glycemic Control: Fasting glucose, HbA1c, and C-peptide.

5. Oxidative Stress & Inflammation

6. Ketone Bodies & Free Fatty Acids: To assess shifts in metabolic fuel utilization.

7. Insulin Sensitivity: Using QUICKI and Adipo-IR indices.

8. CYP8B1 Genotyping & Expression: PCR-based genotyping and qPCR-based expression
profiling to evaluate genetic and transcriptional regulation.

The study integrates molecular genetics (Sanger sequencing and RT-PCR) with clinical
biochemistry and metabolic phenotyping to provide a holistic understanding of
pharmacogenomic effects.

Expected outcomes include:

• Determining whether CYP8B1 polymorphisms influence the degree of weight loss,
lipid and glucose metabolism, and adipokine modulation.

- Comparing the efficacy of empagliflozin vs dapagliflozin in the presence of
different CYP8B1 genotypes.

- Proposing a framework for personalized T2DM and obesity management based on
genetic screening.

Study Type Observational Clinical Trial

________________________________________ Study Duration Estimated Study Period: 6
months per participant

________________________________________ Eligibility Criteria

Inclusion Criteria:

- Aged ≥18 years

- Newly diagnosed T2DM (<6 months)

- BMI ≥30 kg/m²

- No prior antidiabetic treatment

- Consent to genetic testing

Exclusion Criteria:

• Type 1 diabetes or secondary diabetes

• Severe renal impairment (eGFR <45 mL/min/1.73 m²)

• Liver dysfunction or active liver disease

- Pregnancy or lactation

- Allergy to SGLT2 inhibitors

Primary Outcome Measures

• Change in body weight and BMI at 6 months

- Genotype-specific differences in weight loss Secondary Outcome Measures

- Changes in adipokine levels

- Lipid profile changes

- HbA1c and fasting blood glucose improvement

- Differences in insulin sensitivity indices

- Expression levels of CYP8B1 mRNA

- Relationship between genotype and biochemical/metabolic outcomes

Statistical Analysis Plan

- Paired t-tests and ANOVA for within-group and between-group comparisons

- Genotype-phenotype association using chi-square and regression models

- ROC curve analysis for predicting treatment response

- Cox regression for time-to-event data